Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is GLP-1? Benefits, Research & Safety
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Also known as:
Glucagon-Like Peptide-1
GLP-1 (7-36) amide
Incretin
Educational Content Only: This page provides research-based information for educational purposes. GLP-1 is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
1-2 minutes for native GLP-1 (rapidly degraded by DPP-4)
UK Status
Native GLP-1 not used; GLP-1 agonists are approved medications.
EU Status
Multiple GLP-1 receptor agonists approved for diabetes and obesity.
Overview
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone produced primarily by L-cells in the small intestine in response to food intake. It is a member of the incretin hormone family and plays crucial roles in glucose homeostasis, appetite regulation, and energy balance.
GLP-1 is released after eating and produces multiple metabolic effects: it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes feelings of fullness by acting on brain regions controlling appetite. These combined actions make it a key regulator of post-meal metabolism.
The challenge with native GLP-1 is its extremely short half-life—approximately 1-2 minutes—due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). This has led to the development of GLP-1 receptor agonists (such as semaglutide and liraglutide) with modified structures that resist degradation, as well as DPP-4 inhibitors that slow the breakdown of endogenous GLP-1.
Understanding GLP-1 biology has revolutionised the treatment of type 2 diabetes and obesity, leading to some of the most effective medications for these conditions ever developed.
Discovery & History
The discovery of GLP-1 emerged from research into the products of the proglucagon gene in the 1980s. While glucagon had been known since the 1950s, scientists discovered that the same gene encoded multiple peptides depending on where it was expressed.
In the pancreas, proglucagon processing produces glucagon. In the intestine, different processing produces GLP-1 and GLP-2. The identification of GLP-1 and its potent insulinotropic effects in the early 1980s by several research groups generated significant interest.
The observation that GLP-1 enhanced insulin secretion only when glucose was elevated—thus carrying low risk of hypoglycaemia—made it particularly attractive as a potential diabetes treatment. However, the extremely short half-life of native GLP-1 presented a significant therapeutic challenge.
This led to two main therapeutic strategies: development of DPP-4-resistant GLP-1 analogues (GLP-1 receptor agonists like exenatide, liraglutide, and semaglutide) and development of DPP-4 inhibitors (like sitagliptin) that slow endogenous GLP-1 breakdown.
The remarkable success of GLP-1-based therapies, culminating in semaglutide's unprecedented weight loss results, has validated the central importance of this hormone in metabolic regulation.
Mechanism of Action
GLP-1 exerts its effects through the GLP-1 receptor, a G protein-coupled receptor expressed in multiple tissues:
**Pancreatic Effects**
GLP-1 stimulates insulin secretion from beta cells in a strictly glucose-dependent manner—insulin is only released when blood glucose is elevated. It also inhibits glucagon secretion from alpha cells, reducing hepatic glucose output.
**Gastric Effects**
GLP-1 slows gastric emptying, delaying the delivery of nutrients to the small intestine. This contributes to lower post-meal glucose peaks and prolonged satiety.
**Central Nervous System Effects**
GLP-1 receptors in the hypothalamus and brainstem mediate appetite suppression and promote satiety. These central effects are a major contributor to the weight loss seen with GLP-1 therapies.
**Cardiovascular Effects**
GLP-1 receptors are expressed in the heart and blood vessels. GLP-1 may have direct cardioprotective effects, though the precise mechanisms are still being elucidated.
**Beta Cell Preservation**
Animal and cell studies suggest GLP-1 may promote beta cell survival and proliferation, though the relevance of this to long-term human treatment remains under investigation.
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Glucose-dependent insulin secretion (low hypoglycaemia risk)
- 2Improved glycaemic control in type 2 diabetes
- 3Appetite suppression and weight loss
- 4Delayed gastric emptying contributing to satiety
- 5Potential beta cell preservation
- 6Cardiovascular benefits observed with GLP-1 agonists
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Native GLP-1 is not used therapeutically due to short half-life |
| Frequency | N/A for native GLP-1 |
| Duration | N/A |
| Notes | Native GLP-1 is not practical for therapeutic use. Instead, GLP-1 receptor agonists (semaglutide, liraglutide) or DPP-4 inhibitors are used to achieve GLP-1-like effects. |
Administration Routes
Routes studied in research settings (educational only):
- Native GLP-1 would require continuous infusion (not practical)
- GLP-1 analogues: subcutaneous injection or oral (for semaglutide)
| Half-Life | Stability |
|---|---|
| 1-2 minutes for native GLP-1 (rapidly degraded by DPP-4) | Native GLP-1 is highly unstable; analogues have been engineered for stability |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Not applicable for native GLP-1 (not used therapeutically)
- See semaglutide and liraglutide entries for GLP-1 agonist side effects
Rare Risks & Concerns
- GLP-1 agonist class effects include pancreatitis risk, gallbladder disease
Contraindications
- See specific GLP-1 agonist entries for contraindications
UK & EU Regulatory Context
🇬🇧 United Kingdom
Native GLP-1 not used; GLP-1 agonists are approved medications.
🇪🇺 European Union
Multiple GLP-1 receptor agonists approved for diabetes and obesity.
The biological understanding of GLP-1 has led to the development of highly successful medications including semaglutide, liraglutide, and others.
Clinical Studies Summary
GLP-1: From the Discovery of Incretin Hormones to Therapeutic Applications
Comprehensive review of GLP-1 biology and the development of GLP-1-based therapies.
Various review articlesView on PubMed
Looking for GLP-1?
Source research-grade GLP-1 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreSemaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn more